Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.

View your own country’s website

For Media and Investors only.

Germany, September 13^th, 2024 – Theramex, a global pharmaceutical company dedicated to women’s health, is thrilled to announce the first commercial sale of Yselty® (linzagolix) in Germany. Linzagolix is a treatment for uterine fibroids, bringing an option for women to address the unmet need in the space. This milestone marks an addition to the armoury in the fight against uterine fibroids, offering women a much-needed solution for managing moderate to severe symptoms of this condition.

Theramex in-licensed Linzagolix from Kissei Pharmaceutical Co., Ltd. in 2022, and this first sale underscores Theramex’s unwavering commitment to advancing women’s health. By expanding our portfolio with this therapy, we continue to focus on improving the quality of life for women globally, particularly those facing challenging health conditions like uterine fibroids.

“We are thrilled to announce the first sale of Yselty® (Linzagolix), a treatment for uterine fibroids, which marks a significant milestone in our commitment to improving women’s health. This product offers more options for treatment to countless women across Germany. Our partnership with Kissei Pharmaceuticals has been instrumental in bringing Linzagolix to market, and we are grateful for their collaboration and shared vision in advancing healthcare solutions” said Robert Stewart, Theramex CEO.

“We are pleased to be able to bring Linzagolix, discovered by Kissei, to patients through Theramex, a company that has made significant contributions to women’s health. LInzagolix a treatment for uterine fibroids, will help to improve the quality of life of women suffering from uterine fibroid symptoms” said Mutsuo Kanzawa, Kissei Chairman & CEO.

About Yselty® (linzagolix)
Linzagolix is a once daily, oral GnRH receptor antagonist indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age and is approved in the EU.

About Theramex:

Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs, and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.

For further information about Theramex, please contact:

info@theramex.com

About Kissei:

Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.”

As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology/dialysis, gynecology and rare/intractable diseases. Linzagolix has been discovered by Central Research Laboratories of Kissei Pharmaceutical Co., Ltd.

11 December 2023

A dedicated women's health company

Understanding contraceptive options to meet your needs

Supporting you through the menopause

Helping you thrive through osteoporosis

Helping you through the challenges of fertility

Theramex News

Our diverse portfolio helps us deliver on our commitment to Women's Health

Get in touch

Careers

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris.

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris.

You're about to leave our website